Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : GENZYME - THE KING OF THE BIOTECHS -- Ignore unavailable to you. Want to Upgrade?

To: mike mulhearn who wrote (359)	11/19/1998 4:13:00 PM
From: Harold Engstrom	Respond to of 410

Mike, GZMO will have a very long road. Genzyme would not spin off a division if it had near term prospects of profitability. Look at GZTC, a very promising spin off - probably far more promising than GZMO. GZTC has fallen to a small fraction of what it once was. If it pans out, it will be huge, but now you can get it very cheaply indeed relative to its former pricing. I think you will probably have the opportunity to pick up GZMO at a fire sale in the future.